Drug Trial Radar · NCT07719491
Study of GS-0415 and How It Works in People With HIV
Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
112
Planned (sponsor's estimate)
Start
Jul 22, 2026
Primary completion
Aug 2029
Study completion Aug 2029
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Jul 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goals of this clinical study are to learn more about the study drug GS-0415, safety, tolerability, and pharmacokinetics (PK) of single ascending doses (SAD) and multiple ascending doses (MAD) of subcutaneous (SC) and intravenous (IV) GS-0415 in people with HIV-1 (PWH) on antiretroviral treatment. The primary objectives of this study are to evaluate the safety and tolerability of escalating, single and multiple subcutaneous (SC) and intravenous (IV) doses of GS-0415, administered in PWH who are virologically suppressed on antiretroviral therapy (ART) and to evaluate the pharmacokinetics (PK) of GS-0415.
Conditions
- HIV -1 Infection
Interventions
GS-0415Drug
Administered SC or IV
GS-0415 PlaceboDrug
Administered SC or IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs)Time frame: First dose date up to 99 days
- Percentage of Participants Experiencing Clinical Laboratory AbnormalitiesTime frame: First dose date up to 99 days
- Serum Pharmacokinetic (PK) Parameter (After Single Ascending Dose (SAD)): AUCinf of GS-0145Time frame: Up to 43 days
- Serum PK Parameters (SAD): Cmax of GS-0145Time frame: Up to 43 days
- Serum PK Parameters Multiple Ascending Dose (MAD): Dose 1 and Dose 5: AUCtau of GS-0145Time frame: Up to 99 days
- Serum PK Parameters MAD: Dose 1 and Dose 5: Cmax of GS-0145Time frame: Up to 99 days
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California · Recruiting
Georgetown University Medical Center
Washington D.C., District of Columbia · Recruiting
Floridian Clinical Research, LLC
Miami Lakes, Florida · Recruiting
Triple O Research Institute, P.A.
West Palm Beach, Florida · Recruiting
Emory University Hospital Midtown Infectious Disease Clinic
Atlanta, Georgia · Recruiting
Centricity Research CPU - Georgia
Columbus, Georgia · Recruiting
Indiana CTSI Clinical Research Center
Indianapolis, Indiana · Recruiting
Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
Boston Medical Center
Boston, Massachusetts · Recruiting
PPD Development, LP
Las Vegas, Nevada · Recruiting
St. Michaels Medical Center
Newark, New Jersey · Not yet recruiting
Jacobi Medical Center
The Bronx, New York · Recruiting
Duke Early Phase Clinical Research Unit
Durham, North Carolina · Recruiting
Wake Forest University Health Sciences
Winston-Salem, North Carolina · Recruiting
University of Cincinnati College of Medicine
Cincinnati, Ohio · Recruiting
The Ohio State University Medical Center Infectious Diseases Clinic
Columbus, Ohio · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.